...
首页> 外文期刊>Journal of Cancer >Prognostic Value of Proliferation Markers: Immunohistochemical Ki-67 Expression and Cytometric S-Phase Fraction of Women with Breast Cancer in Libya
【24h】

Prognostic Value of Proliferation Markers: Immunohistochemical Ki-67 Expression and Cytometric S-Phase Fraction of Women with Breast Cancer in Libya

机译:增殖标志物的预后价值:利比亚乳腺癌妇女的免疫组化Ki-67表达和细胞计数S期分数。

获取原文

摘要

Background: We evaluated the association of the immunohistochemical Ki-67 expression, and S-phase fraction with clinicopathological variables and patient outcome. Patients and methods: Histological samples from 100 primary Libyan breast carcinoma patients were retrospectively studied with monoclonal antibody to Ki-67. S-phase fraction was determined by DNA image cytometry. Results: The median Ki-67 percentage for all tumors was 27.5%, ranging from 1 to 80% and the median S-phase fraction (SPF) was 11%, ranging from 0 to 62 %. Tumors with high Ki-67 expression were found in 76% of patients and with high SPF values in 56%. Ki-67 expression was more frequent in tumors with high SPF than low SPF. High Ki-67 and high SPF were associated with advanced stages, poor differentiation of tumors, positive lymph nodes, and distant metastasis. The Ki-67 was associated with hormone receptor negative tumors. The SPF was higher in young patients (Conclusions: The SPF value is useful cell proliferation marker to assess tumor prognosis. These markers may reflect the aggressive behavior of Libyan breast cancer and predict of the recurrence. It is therefore important to take these markers into consideration to select a high risk subgroup of the patients for intensive treatment.
机译:背景:我们评估了免疫组化Ki-67表达和S期分数与临床病理变量和患者预后的关系。患者和方法:使用针对Ki-67的单克隆抗体回顾性研究了100例原发利比亚乳腺癌患者的组织学样本。通过DNA图像细胞术确定S期分数。结果:所有肿瘤的中位数Ki-67百分比为27.5%,范围为1至80%,中位数S期分数(SPF)为11%,范围为0至62%。在76%的患者中发现了高Ki-67表达的肿瘤,在56%的患者中发现了高SPF值。高SPF的肿瘤比低SPF的Ki-67表达更为频繁。高Ki-67和高SPF与晚期,肿瘤分化不良,淋巴结阳性和远处转移有关。 Ki-67与激素受体阴性肿瘤有关。年轻患者的SPF较高(结论:SPF值是评估肿瘤预后的有用细胞增殖标志物。这些标志物可能反映利比亚乳腺癌的侵袭性行为并预测复发。因此,重要的是要考虑这些标志物选择高危患者亚组进行强化治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号